<?xml version="1.0" encoding="UTF-8"?><OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd"><responseDate>2026-10-19T00:27:18Z</responseDate><request verb="GetRecord" identifier="oai:ebyu-rdlopen.rawdatalibrary.net:ebyu/12873" metadataPrefix="oai_dc">https://ebyu-rdlopen.rawdatalibrary.net/oai/request</request><GetRecord><record><header><identifier>oai:ebyu-rdlopen.rawdatalibrary.net:ebyu/12873</identifier><datestamp>2026-10-18T20:27:43Z</datestamp><setSpec>openaire</setSpec><setSpec>driver</setSpec><setSpec>com_ebyu_10000</setSpec><setSpec>col_ebyu_10001</setSpec></header><metadata><oai_dc:dc xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd"><dc:title>The Molecular Mechanism of the Effect of Carvacrol on Desflurane Inhalation-Induced Liver Damage in Rats</dc:title><dc:creator>Disli, Zeliha Korkmaz</dc:creator><dc:creator>Acun Delen, Leman</dc:creator><dc:creator>Tas, Hakan Gokalp</dc:creator><dc:creator>Kuyrukluyildiz, Ufuk</dc:creator><dc:creator>Disli, Olcay Murat</dc:creator><dc:creator>Yazici, Gulce Naz</dc:creator><dc:creator>Coban, Abdulkadir</dc:creator><dc:creator>Suleyman, Halis</dc:creator><dc:subject>antioxidant</dc:subject><dc:subject>carvacrol</dc:subject><dc:subject>desflurane</dc:subject><dc:subject>hepatotoxicity</dc:subject><dc:subject>ınhalation anesthesia</dc:subject><dc:subject>immunoglobulin enhancer binding protein</dc:subject><dc:subject>interleukin 1beta</dc:subject><dc:subject>spasmolytic agent</dc:subject><dc:subject>tumor necrosis factor</dc:subject><dc:subject>alanine aminotransferase blood level</dc:subject><dc:subject>animal experiment</dc:subject><dc:subject>animal model</dc:subject><dc:subject>animal tissue</dc:subject><dc:subject>antibacterial activity</dc:subject><dc:subject>antifungal activity</dc:subject><dc:subject>antiinflammatory activity</dc:subject><dc:subject>antineoplastic activity</dc:subject><dc:subject>antioxidant activity</dc:subject><dc:subject>Article</dc:subject><dc:subject>aspartate aminotransferase blood level</dc:subject><dc:subject>controlled study</dc:subject><dc:subject>drug induced cancer</dc:subject><dc:subject>enzyme linked immunosorbent assay</dc:subject><dc:subject>histopathology</dc:subject><dc:subject>Kupffer cell</dc:subject><dc:subject>liver</dc:subject><dc:subject>liver injury</dc:subject><dc:subject>liver toxicity</dc:subject><dc:subject>male</dc:subject><dc:subject>metabolite</dc:subject><dc:description>The metabolite of desflurane has been linked to hepatotoxicity. Carvacrol possesses antioxidant, antibacterial, antifungal, anticancer, anti-inflammatory, and spasmolytic properties, according to research. Our goal is to demonstrate that carvacrol protects rats’ livers against repeated doses of desflurane. Healthy (HG), desflurane (DS), and carvacrol + desflurane treatment (CDS) groups were formed from 18 albino male Wistar rats. A single dosage of carvacrol and 6% desflurane was given for 2 h on the 0th and 8th days. In the CDS group, the ALT and AST, MDA, TOS, NF-xB, TNF-α IL1 β levels were lower compared to the DS group (p &lt; 0.001). The tGSH,TAS levels were found to be higher in the CDS group compared to the DS group (p &lt; 0.001). It was determined that the mean degeneration level, Kupffer cell activation and PMNL infiltration were found to be lower compared to the DS group (p &lt; 0.05).We confirmed that carvacol can be used in the treatment of desflurane-related liver injury. © 2022, Colegio de Farmaceuticos de la Provincia de Buenos Aires. All rights reserved.</dc:description><dc:publisher>Colegio de Farmaceuticos de la Provincia de Buenos Aires</dc:publisher><dc:date>2022</dc:date><dc:type>Article</dc:type><dc:identifier>https://rdlopen.rawdatalibrary.net/r/ebyu/12873</dc:identifier><dc:identifier>0326-2383</dc:identifier><dc:language>en</dc:language><dc:relation>Latin American Journal of Pharmacy</dc:relation><dc:rights>info:eu-repo/semantics/openAccess</dc:rights><dc:type>info:eu-repo/semantics/article</dc:type><dc:identifier>https://ebyu-rdlopen.rawdatalibrary.net/tr/items/ebyu/12873</dc:identifier></oai_dc:dc></metadata></record></GetRecord></OAI-PMH>